Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seoul National University Hospital
Breast cancer patients who received neoadjuvant chemotherapy and is predicted to have achieved pathologic complete response (pCR) on MRI will enrolled. The enrolled patients will undergo either US-guided multiple core needle biopsy or US-guided vacuum-assisted biopsy of the tumor bed where it had been marked with an indicator (clip). The patient will undergo subsequent wide excision of the tumor bed. Histopathologic findings of the biopsy and the surgical specimen will be compared for pCR, and the ability of preoperative biopsies to predict pCR will be evaluated.
Age
18–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients
with unilateral primary cancer pathologically confirmed before neoadjuvant chemotherapy (NAC)
who received NAC
with detectable lesion / clip marker on ultrasound
with cT1-T3 tumors
clinical and imaging complete or near-complete response on MRI
with informed consent
You may not be if
Multifocal cancer
Residual microcalcification
Contralateral breast cancer
Clareo Health | Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
